Navigation Links
NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
Date:2/12/2009

PRINCETON, NJ, Feb. 12 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and manufacturer of medical products that fight infection and inflammation, today announced the results of a special meeting of shareholders. The special meeting of shareholders was called to consider a special resolution ("Special Resolution") pursuant to section 38(1) of the Business Corporations Act (Alberta) to reduce the stated capital of the outstanding NUCRYST common shares by an amount equal to the product of the number of common shares outstanding on the date of the meeting and $0.80 for the purpose of distributing $0.80 cash per share to the common shareholders of NUCRYST.

The distribution which will total $14.7 million equals approximately 59% of NUCRYST's $25.0 million in cash and cash equivalents as of January 31, 2009. NUCRYST set a distribution payable date of February 25, 2009.

The Special Resolution was passed and February 17, 2009 was set as the record date for the distribution. The Toronto Stock Exchange ("TSX") has determined that mandatory special settlement rules will be applied and the common shares will commence trading ex-distribution on the TSX at the opening of the markets on February 17, 2009.

Under NASDAQ OMX rules, the shares will continue to trade with the distribution until its ex-distribution date of February 26, 2009.

NUCRYST also announced the resignation of Thomas E. Gardner from the Board of Directors, effective immediately. Mr. Gardner previously served as Chairman, President, & Chief Executive Officer of NUCRYST until January 2009.

NUCRYST will release its 2008 fourth quarter and full year financial results on Tuesday, February 17, 2009. A conference call will be held that morning to discuss the financial results as well as the impact of the return of capital on NUCRYST's business plans.

All amounts are in U.S. dollars.

About NUCRYST Pharmaceuticals Corp.


'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NUCRYST and Smith & Nephew Revise Agreements
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST Pharmaceuticals announces 2007 third quarter results
4. NUCRYST Pharmaceuticals announces year-end results
5. NUCRYST Announces Senior Management Change
6. NUCRYST Announces Management Realignment and R&D Portfolio Change
7. NUCRYST Announces First Quarter 2008 Financial Results
8. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
9. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
10. NUCRYST Receives Deficiency Notice from NASDAQ
11. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... released by Blue Star Nutraceuticals designed to help maximize ... ingredients that optimizes the body’s absorption of glucose has ... review. , “The main purpose behind Glycodrive is ... that builds lean muscle,” reports Michaels. “Carbs are essential ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... plastic surgery providers in Turkey has gone up more ... of growth. The medical tourism company also reported total ... since October 2012. , The company’s professional strategy has ... in Turkey — ultimately designed for patient comfort and ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 A ... the world to combat an epidemic that, left unchecked, could ... no, they are not headed to Africa. John Rogers, the ... headed to North Korea to fight a disease most think ... the US some 80 years ago is on the comeback ...
(Date:9/30/2014)... 2014) Levothyroxine is considered the gold standard therapy ... review of therapies for the condition including combining ... assessment, say a team of investigators.,1Their analysis, published as ... , finds insufficient consistent data exist to recommend a ... sold under various trade names, such as Synthroid ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... released software program will let health authorities at the ... speeding the detection of new cases and the implementation ... was developed by a team of epidemiologists and computer ... (MIDAS), an international program supported by the National Institutes ...
... Cover Election, Customer Service and Other Work Life Topics ... That Counter Recent ... those,surveyed in the 2007 Annual Work+Life Fit Reality Check believe the ... offer and individuals to have more work life flexibility.,The telephone survey ...
... Avani to Represent Dermatology Products Featuring Invisicare(R), ... Inc. (OTC,Bulletin Board: SKVI) / (Website: ... has signed a marketing agreement with Avani,International ... it was granted a comprehensive patent in ...
... Dec. 6 Insmed Inc. (Nasdaq:,INSM), a developer of ... at the IBC 5th Annual Global Follow-On Biologics,Conference on ... The conference, to be held at the Hyatt Regency ... through Tuesday, December,11th, and will bring together corporate, regulatory, ...
... Health, Inc. (Amex: OPK ),today reported that the ... of wet age-related macular degeneration (wet,AMD), was named one ... III,clinical trials during the third quarter of 2007. The ... to Watch report issued by Thomson,Scientific Inc. Thomson,s industry ...
... you get for the nut,that has everything, including more than ... talking therapy doll?, You can at once give a ... it, their own personal and portable psychotherapist. The,Ask Doctor Chuck ... could,earn you the undying gratitude of the rest of your ...
Cached Medicine News:Health News:New software to aid early detection of infectious disease outbreaks 2Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 2Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 3Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 4Health News:Employees Want the Next President's Agenda to Make Work Life Flexibility Easier for Companies and Individuals 5Health News:Skinvisible Signs Marketing Agreement for India 2Health News:Skinvisible Signs Marketing Agreement for India 3Health News:Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 2Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 3Health News:OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials 4Health News:The Cure for Holiday Stress 2
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
(Date:9/30/2014)... Ind. , Sept. 30, 2014  The orthopedic specialists ... the nation,s No. 6 orthopedic group by US News ... Active Adults," a series of free, public seminars to ... all over the world come to see the knee ... procedures are now available at Munster Specialty Surgery Center. ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... , LITTLE FALLS, N.J., Dec. 2 ... the results for its first quarter ended October 31, 2009 on ... to discuss the results at 11:00 AM ET. Participating in ... President and CEO; Seth R. Segel, Executive Vice President; Craig A. ...
... , , CENTENNIAL, Colo., Dec. 2 ... bone and soft tissue allografts for use in surgical procedures ... substitutes, today announced its sponsorship of a truly iconic symbol ... Life float in the January 1, 2010 Tournament of Roses ...
Cached Medicine Technology:Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2009 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss....
... VelaSmooth is the first ... device with the revolutionary elos ... Radio Frequency and Infrared Light ... with suction to reduce the ...
... was designed with the physician, staff ... you the best economy exam room ... does not skimp on patient comfort. ... can easily position patients so that ...
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
Medicine Products: